Esperion Therapeutics
ESPR
#6749
Rank
HK$3.72 B
Marketcap
HK$18.90
Share price
-3.57%
Change (1 day)
154.72%
Change (1 year)

P/E ratio for Esperion Therapeutics (ESPR)

P/E ratio as of November 2024 (TTM): -0.8617

According to Esperion Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.861702. At the end of 2022 the company had a P/E ratio of -1.75.

P/E ratio history for Esperion Therapeutics from 2013 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-1.75235.54%
2021-0.5230-89.34%
2020-4.91-70.96%
2019-16.9176.89%
2018-6.10-34.95%
2017-9.38149.46%
2016-3.76-61.83%
2015-9.85-45.44%
2014-18.1128.45%
2013-7.90

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-4.67 442.17%๐Ÿ‡บ๐Ÿ‡ธ USA
84.9-9,955.82%๐Ÿ‡บ๐Ÿ‡ธ USA
14.1-1,734.05%๐Ÿ‡บ๐Ÿ‡ธ USA
22.0-2,650.23%๐Ÿ‡บ๐Ÿ‡ธ USA
-16.4 1,802.12%๐Ÿ‡บ๐Ÿ‡ธ USA
-1.75 103.09%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.